Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,510 JPY | -1.11% | -3.33% | -10.41% |
Sales 2024 | 1,604B 10.29B | Sales 2025 * | 1,656B 10.63B | Capitalization | 2,739B 17.57B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 109M | Net income 2025 * | 94.35B 605M | EV / Sales 2024 | 1.84 x |
Net Debt 2024 * | 503B 3.23B | Net Debt 2025 * | 512B 3.29B | EV / Sales 2025 * | 1.96 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
29.1
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
4.92% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | -1.01% | ||
1 week | -3.23% | ||
Current month | -0.13% | ||
1 month | +4.56% | ||
3 months | -8.64% | ||
6 months | -14.12% | ||
Current year | -10.32% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 19-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 0 M€ | +11.38% | ||
2.09% | 0 M€ | +13.17% | ||
2.01% | 0 M€ | +20.15% | ||
1.99% | 0 M€ | +13.81% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 1,510 | -1.11% | 4 597 000 |
24-05-10 | 1,528 | -0.88% | 6,638,000 |
24-05-09 | 1,541 | -0.23% | 5,938,700 |
24-05-08 | 1,544 | -1.15% | 7,330,800 |
Delayed Quote Japan Exchange, May 13, 2024 at 01:51 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.32% | 17.57B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 4503 Stock